Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL1062441

COCCNC(=O)c1sc2c(c1OC)c(=O)n(Cc1ccccn1)c1ccccc21.O=C(O)C(F)(F)F

nearest known ligand 0.52

Full drug profile on Sugi Atlas →

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.46
▸ TP53 P04637 4/20 0.42
▸ THRB P10828 1/20 0.42
▸ ALDH1A1 P00352 6/20 0.41
▸ KDM4E B2RXH2 4/20 0.41
▸ LMNA P02545 3/20 0.41
▸ TSHR P16473 3/20 0.41
▸ PKM P14618 1/20 0.41
▸ SMN1; SMN2 Q16637 4/20 0.39
▸ HTT P42858 3/20 0.39
▸ USP2 O75604 2/20 0.39
▸ NPSR1 Q6W5P4 2/20 0.39
▸ RAB9A P51151 1/20 0.38
▸ MAPT P10636 2/20 0.38
▸ PLA2G2A P14555 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ FEN1 P39748 1/20 0.36
▸ RXFP1 Q9HBX9 1/20 0.36
▸ MAPK1 P28482 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10314253 0.94 KMT2A (0.48) KMT2ATP53THRBALDH1A1KDM4E
Trifluoroacetic Acid SCHEMBL1061583 0.93 ALDH1A1 (0.48) KMT2ATP53ALDH1A1KDM4ELMNA
Trifluoroacetic Acid SCHEMBL1061358 0.92 ALDH1A1 (0.39) KMT2ATP53THRBALDH1A1KDM4E
Trifluoroacetic Acid SCHEMBL1064358 0.92 ALDH1A1 (0.45) KMT2ATP53ALDH1A1KDM4ELMNA
Trifluoroacetic Acid SCHEMBL1059829 0.91 RXFP1 (0.42) KMT2ATP53THRBALDH1A1KDM4E
Trifluoroacetic Acid SCHEMBL1060742 0.91 L3MBTL1 (0.41) KMT2ATP53THRBALDH1A1KDM4E
Trifluoroacetic Acid SCHEMBL1063948 0.91 EPHX2 (0.40) KMT2ATP53THRBALDH1A1KDM4E
Trifluoroacetic Acid SCHEMBL1061926 0.90 ALDH1A1 (0.40) TP53THRBALDH1A1KDM4ELMNA
Trifluoroacetic Acid SCHEMBL1063033 0.89 ALDH1A1 (0.43) KMT2ATP53ALDH1A1KDM4ELMNA
Trifluoroacetic Acid SCHEMBL1062006 0.89 KDM4E (0.43) KMT2ATP53ALDH1A1KDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2247588-B1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL (JP) 2016-04-13 — — EP disclosed
US-8399449-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-03-19 — — US disclosed
US-8217176-B2 Fused heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-07-10 — — US disclosed
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-01-06 — — US disclosed
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-09-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110003788-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KMT2A 453/4885TP53 3556/4885THRB 469/4885
US-20090227561-A1 FUSED HETEROCYCLIC DERIVATIVE AND USE THEREOF SMO, NR1H2, NR1H4 KMT2A 386/4885TP53 3584/4885THRB 496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback